News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

J.P. Morgan’s Commercial Bank Expands Life Sciences Team To Serve Fast-Growing Industry Team Adds Experienced Bankers And Expands To Key U.S. Markets



7/27/2017 11:11:44 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
NEW YORK – J.P. Morgan has rapidly expanded its Life Sciences team within its Commercial Banking business to help companies meet their unique risks, opportunities and challenges. In just one year, the team has recruited key talent and created a national presence, with staff in key Life Sciences markets across the U.S., including:

• Boston
• Houston
• Iselin
• Minneapolis
• New York City
• Palo Alto
• Philadelphia
• Raleigh-Durham
• San Diego

Peter Meath joined J.P. Morgan’s Commercial Bank last year to create the Life Sciences group to serve companies at every stage of growth across the biopharmaceuticals and medical technology industries, including biotechnology, pharmaceuticals, medical devices and diagnostics.

The group continues to build its geographic presence across the U.S., most recently growing its West Coast team with the hiring of Linda Le Beau, industry executive overseeing the western region from Palo Alto. Linda previously was a managing director at East West Bank. Joining Linda are recent hires Brett Shealy, vice president in Palo Alto, and Kevin Filer, vice president in San Diego, who joined from Wells Fargo and Bank of America, respectively.

“We are like a specialty life sciences bank within a bank with the strength of J.P. Morgan behind us,” said Meath, managing director and industry manager for Life Sciences within the Commercial Bank. “Our clients will benefit from our deep industry expertise, global resources and access to the firm’s full range of products and capabilities, from Commercial Banking to Investment Banking to Asset Management. We are here to help them succeed, from their early stage business strategies and beyond.”

Prior to joining J.P. Morgan, Meath co-founded Square 1 Bank and headed the Southeast and Mid-Atlantic regions.

“This is an exciting time to serve companies benefiting from the changing demographics and health-care legislation in the U.S.,” said Scott Geller, head of the Specialized Industries practice for middle market banking at J.P. Morgan. “We can make banking easier for complex and rapidly changing industries in the innovation economy.”

J.P. Morgan’s middle marketing banking business recently reached a key milestone of having a local presence in all top 50 Metropolitan Statistical Areas (MSAs) in the U.S. The group provides businesses with comprehensive financial solutions across 16 specialized industries including life sciences, technology and healthcare. It works closely with the Corporate and Investment Bank’s Healthcare practice to deliver advisory solutions, products and capital markets expertise to clients.

This transmission may contain information that is proprietary, privileged, confidential, and/or exempt from disclosure under applicable law. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or use of the information contained herein (including any reliance thereon) is STRICTLY PROHIBITED. If you received this transmission in error, please immediately contact the sender and destroy the material in its entirety, whether in electronic or hard copy format. Although this transmission and any attachments are believed to be free of any virus or other defect that might affect any computer system into which it is received and opened, it is the responsibility of the recipient to ensure that it is virus free and no responsibility is accepted by JPMorgan Chase & Co., its subsidiaries and affiliates (collectively, "JPMC"), as applicable, for any loss or damage arising in any way from its use. Please note that any electronic communication that is conducted within or through JPMC's system is subject to interception, monitoring, review, retention and external production; may be stored or otherwise processed in countries other than the country in which you are located; and will be treated in accordance with JPMC's policies and applicable laws and regulations.

Read at BioSpace.com


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES